ARA-290

Peptide research

ARA-290

Available documentary data and items still to verify are detailed below.

Preorder · dispatch within 30 days after payment is credited.

Price incl. VAT€55.00
AvailabilityPreorder
SKUNL-ARA-290-16MG

Loading availability…

02 — Information to verify

Product details

Overview

ARA-290, also called cibinetide, is a synthetic 11-amino-acid peptide designed from a structural region of erythropoietin (EPO). Research investigates cellular injury responses and signalling associated with the innate repair receptor (IRR). Format: 16 mg per vial as lyophilized powder.

Structure and technical data

Technical data

The reference sequence is pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. Its first residue is pyroglutamate. ARA-290 is not the full EPO hormone: the literature describes it as a non-erythropoietic derivative.

ARA-290
ARA-290 · 2D molecular structure — PubChem. PubChem CID 91810664
Sequence
pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
Molecular formula
C51H84N16O21
Reported molecular mass
1257.3 g/mol
CAS number
1208243-50-8
PubChem CID
91810664
Reported synonyms
Cibinetide; ARA 290; pHBSP

Reference molecular data.

View the PubChem record — PubChem CID 91810664

Research context

The cited publications discuss experimental inflammation models, IRR signalling and small nerve fibre abnormalities. They include preclinical findings and specific clinical investigations, without establishing efficacy or safety of this commercial material in people.

A peptide designed from EPO structure

ARA-290 was designed from a surface in erythropoietin’s helix-B region. The name pHBSP means pyroglutamate helix B surface peptide. Its shortened sequence is of interest in tissue-protection research, distinct from full EPO and its erythropoietic activity.

The IRR receptor complex

The literature describes IRR as a complex involving the EPO receptor and the common β subunit CD131. Research examines its participation in cellular responses to injury or inflammation, a context distinct from red blood cell production.

From preclinical models to exploratory studies

Research includes nerve-injury models and exploratory clinical studies of small-fibre abnormalities. Reported endpoints include morphological measurements and symptoms and must be interpreted within each study’s design. This research vial is not equated with the investigational materials used in those studies.

Sequence identity

The pGlu notation identifies the cyclic N-terminal group. Technical descriptions should retain this feature and distinguish it from an unmodified glutamine sequence. Biological findings depend on the model and experimental conditions.

Batch documentation

Molecular data describe the reference compound. Identity, content and purity of the supplied material must be checked against its batch certificate. This page does not attribute another supplier’s tests or results to this product. For laboratory research only; not for human or veterinary use.

Exploratory small-fibre study

Placebo-controlled sarcoidosis study assessing corneal fibres and symptoms in a specific population.

IRR and neuropathy research

Review of mechanisms, preclinical models and exploratory evidence concerning the IRR system.

10.1097/PR9.0000000000000566

What does the mg format mean?

It indicates nominal mass per vial, not an mg/ml concentration or an instruction for use. In the blend, 10+3 mg identifies the two components separately.

Does the structure represent the supplied batch?

The PubChem figure depicts the reference compound. Identity, chemical form, content and purity of actual material require documentation for the corresponding batch.

How are storage and stability checked?

Consult the label, safety data sheet and batch-specific instructions. Molecular properties alone do not establish an expiry date or an after-opening lifetime for this product.

Catalog of products presented for research activities. Not for human or veterinary use. This notice does not replace verification of applicable rules.